Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
136-150 of 4547 results
XyloCor’s cardiovascular gene therapy gets FDA fast track designation
The US Food and Drug Administration (FDA) has granted Fast Track designation to XyloCor Therapeutics’ lead product candidate XC001 (AdVEGF-All6A+), a cardiovascular angiogenic gene therapy.
Drug Research > Drug Discovery & Development > News
Novartis’ Sandoz, Durect sign $293m deal for pain killer Posimir
By PBR Staff Writer
Biopharmaceutical firm Durect has entered into a development and commercialization agreement with Novartis subsidiary Sandoz for Posimir (Saber-Bupivacaine) in the US.
Drug Research > Drug Discovery & Development > News
Vivet raises €37.5m to advance gene therapies for metabolic diseases
Vivet Therapeutics, which is focused on developing novel gene therapies for rare, inherited metabolic diseases, has raised €37.5m in a Series A financing round.
Drug Research > Drug Discovery & Development > News
Novartis exercises option with Conatus for NASH treatment
By PBR Staff Writer
Novartis has exercised its option with ConatusPharmaceuticals for an exclusive license for the worldwide development and commercialization of emricasan, a potential treatment for non-alcoholic steatohepatitis (NASH).
Drug Research > Drug Discovery & Development > News
Sosei to invest in UK biopharmaceutical firm MiNA Therapeutics
Sosei has agreed to make an investment in and acquire an exclusive option to potentially acquire MiNA Therapeutics, a private UK biopharmaceutical company.
Drug Research > Drug Discovery & Development > News
AstraZeneca, Pieris form $2.1bn respiratory drug collaboration
By PBR Staff Writer
AstraZeneca will develop new inhaled respiratory treatments based on Pieris Pharmaceuticals’ Anticalin platform through a collaboration that could generate more than $2bn for the US firm.
Drug Research > Drug Discovery & Development > News
AstraZeneca’s bladder cancer drug imfinzi gets accelerated approval from FDA
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Imfinzi (durvalumab) for previously treated patients with advanced bladder cancer.
Drug Research > Drug Discovery & Development > News
Shire licenses dry-eye treatment from Parion Sciences
Shire has secured exclusive global rights to develop Parion Sciences' Phase II-stage epithelial sodium channel (ENaC) inhibitor P-321 for the potential treatment of dry eye.
Drug Research > Drug Discovery & Development > News
Bristol-Myers Squibb not to exercise its option to buy F-star Alpha
Bristol-Myers Squibb will not exercise its option to buy F-star Alpha and its lone asset, FS102, an antibody fragment targeting human epidermal growth factor receptor 2 (HER2).
Drug Research > Drug Discovery & Development > News
Takeda, Harrington to advance development of rare disease therapeutics
Takeda Pharmaceutical has entered into a multi-year partnership with Harrington Discovery Institute at University Hospitals in Cleveland, Ohio to advance the development of rare disease rherapeutics.
Drug Research > Drug Discovery & Development > News
Gates Foundation leads $45.5m round for biotechnology firm Arsanis
Clinical-stage biopharmaceutical firm Arsanis has secured $45.5m in a Series D financing round led by the Bill & Melinda Gates Foundation.
Drug Research > Drug Discovery & Development > News
H3 Biomedicine, Foundation Medicine extend precision oncology collaboration
H3 Biomedicine has extended its multi-year collaboration, which was signed in February 2015, with Foundation Medicine to discover and develop precision medicines in oncology.
Drug Research > Drug Discovery & Development > News
Novartis signs collaboration deal with Parvus for diabetes nanomedicine
By PBR Staff Writer
Pharma giant Novartis has acquired the exclusive, worldwide rights for Parvus Therapeutics’ Navacim technology for type 1 diabetes (T1D) treatment.
Drug Research > Drug Discovery & Development > News
Alpine Immune Sciences to merge with Nivalis Therapeutics
Alpine Immune Sciences has agreed to merge with a subsidiary of Nivalis Therapeutics in an all-stock transaction.
Drug Research > Drug Discovery & Development > News
HitGen, Pfizer to build and screen novel DNA-encoded libraries
HitGen has entered into a multi-year research collaboration and license agreement with Pfizer to build and screen novel DNA-encoded libraries (DELs) to potentially discover unique small molecule leads to be used in developing drugs.
Drug Research > Drug Discovery & Development > News
136-150 of 4547 results